Inclusion Criteria:

- Inoperable patients

- histologically confirmed HCC or patients who refuse surgery and who otherwise (e.g.
due to the advanced tumor stage) are not applicable for palliative local therapy
(e.g. PEI, TACE, RFTA).

- Age: 18 years or older

Exclusion Criteria:

General:

- Patient with symptomatic Cholecyst-/Choledocholithiasis

- Patient with severe psychiatric disease.

- Participation in another clinical trial within the last 4 weeks.

- Simultaneous participation in another clinical examination.

- Legally incapacitated patient, who is not able, to understand nature, meaning and
consequence of the study.

- Continuous drug or alcohol abuse.

- Patient with known HIV infection and antiretroviral therapy.

- Patient with not controllable infection disease.

- Pregnancy.

Study- and indication-specific exclusion criteria:

- Secondary malignant tumor without complete remission.

- Secondary malignant tumor with complete remission but current adjuvant therapy.

- Preliminary or current therapy with tamoxifen

- Pretreatment of the HCC.

- First-time diagnosis > 6 months before inclusion into the study.

- Severe hepatic encephalopathy, refractory to any treatment.

- Patients with operable HCC.

- Contraindication to i.m. injections.

- Hypersensitivity to octreotide.